Manish R Patel
Overview
Explore the profile of Manish R Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
5572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valantinas A, Mustard J, Chevrier V, Mangold N, Bishop J, Pommerol A, et al.
Nat Commun
. 2025 Feb;
16(1):1712.
PMID: 40000645
Iron oxide-hydroxide minerals in Martian dust provide crucial insights into Mars' past climate and habitability. Previous studies attributed Mars' red color to anhydrous hematite formed through recent weathering. Here, we...
2.
Horwitz S, Feldman T, Ye J, Khodadoust M, Munoz J, Hamlin P, et al.
Leuk Lymphoma
. 2025 Feb;
:1-11.
PMID: 39921522
In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], = 29); PTCL-not otherwise specified [NOS], = 11; and...
3.
Erickson S, Manning B, Kumar A, Patel M
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796666
Thoracic malignancies (lung cancers and malignant pleural mesothelioma) are prevalent worldwide and are associated with high morbidity and mortality. Effective treatments are needed for patients with advanced disease. Cell therapies...
4.
Taylor M, Naing A, Powderly J, Woodard P, Chung L, Lin W, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39567210
Purpose: In this first-in-human dose escalation study, the safety and efficacy of IO-108, a fully human monoclonal antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), was investigated in patients with advanced...
5.
Patel M, Falchook G, Wang J, Imedio E, Kumar S, Miah K, et al.
Target Oncol
. 2024 Nov;
20(1):127-138.
PMID: 39560862
Background: Adavosertib (AZD1775) is a small-molecule Wee1 inhibitor. Durvalumab is a PD-L1 inhibitor. Objective: The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of adavosertib plus durvalumab were evaluated in patients...
6.
Patel M, Begnaud A, Blackmon S, Dudek A, Fujioka N, Harewood J, et al.
J Cancer Educ
. 2024 Oct;
PMID: 39438400
Lung cancer patient education resources that address barriers to health literacy, improve understanding, and demonstrate improved patient outcomes are limited. Our study aim was to evaluate and report on learner...
7.
Shah N, Wang M, Roeker L, Patel K, Woyach J, Wierda W, et al.
Haematologica
. 2024 Oct;
110(1):92-102.
PMID: 39363864
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase I/II BRUIN study evaluated pirtobrutinib, a highly selective...
8.
Chen C, Khanna V, Kummar S, Abdul-Karim R, Sommerhalder D, Tolcher A, et al.
Cancer Res Commun
. 2024 Aug;
4(9):2415-2426.
PMID: 39177285
Purpose: In preclinical models, glucocorticoid receptor (GR) signaling drives resistance to taxane chemotherapy in multiple solid tumors via upregulation of antiapoptotic pathways. ORIC-101 is a potent and selective GR antagonist...
9.
Gainor J, Patel M, Weber J, Gutierrez M, Bauman J, Clarke J, et al.
Cancer Discov
. 2024 Aug;
14(11):2209-2223.
PMID: 39115419
mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens to induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of...
10.
Wierda W, Shah N, Cheah C, Lewis D, Hoffmann M, Coombs C, et al.
Lancet Haematol
. 2024 Jul;
11(9):e682-e692.
PMID: 39033770
Background: Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated...